

Italfarmaco S.p.A. study no: DSC/13/2984/05

Page 1 of 1

Table 14.2.4.2 Summary of Reduction of GH Level < 2.5 (mcg/litre) at the End of the Treatment Period
(Intent-to-treat Analysis Set)

Period		Treatment			
		100 mcg Octreotide (N=41) n (%)	500 mcg ITF2984 (N=43) n (%)	1000 mcg ITF2984 (N=47) n (%)	2000 mcg ITF2984 (N=42) n (%)
1	Yes	0	0	2 (4.3)	6 (14.3)
	No	11 (26.8)	12 (27.9)	7 (14.9)	6 (14.3)
2	Yes	4 (9.8)	0	3 (6.4)	4 (9.5)
	No	8 (19.5)	8 (18.6)	9 (19.1)	7 (16.7)
3	Yes	2 (4.9)	2 (4.7)	2 (4.3)	4 (9.5)
	No	9 (22.0)	9 (20.9)	9 (19.1)	4 (9.5)
4	Yes	1 (2.4)	1 (2.3)	1 (2.1)	5 (11.9)
	No	6 (14.6)	10 (23.3)	10 (21.3)	6 (14.3)
Overall	Yes	7 (17.1)	3 (7.0)	8 (17.0)	19 (45.2)
	No	34 (82.9)	39 (90.7)	35 (74.5)	23 (54.8)

N = the number of subjects in the analysis set receiving the specified treatment.

n = the number of subjects with a measurement.

(%) = n/N*100.

Source: Listing 16.2.6.1

PROGRAM NAME:T_GHIGF_02.SAS

DATE OF RUN:12SEP2016

TIME OF RUN: 11:55:24

DATE OF EXTRACTION:25MAY2016